Award of task order 3 entitled "a dual AKT/PDPK1 inhibitor for actinic keratosis and skin cancer prevention in immunocompromised individuals"
Ended Awarded Last action
- Contract number
- 75N91018F00003
- Awardee
-
University Of Illinois UEI W8XEAJDKMXH3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,273,213
Award facts
- Opportunity
-
- N01CN4500045 Solicitation number
- Contract value 100% obligated
- $2,273,213.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Urbana, IL 61801, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$90 | |
| Supplemental Agreement for work within scope | $165,713 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$30,173 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $13,932 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $408,781 | |
| Supplemental Agreement for work within scope | $17,000 | |
| Other Administrative Action | $451 | |
| Original award | $1,697,599 |
Show all 19
About this award
The National Cancer Institute issued a delivery order to the University of Illinois on September 17, 2018, for preclinical toxicology and pharmacology research on a dual AKT/PDPK1 inhibitor for actinic keratosis and skin cancer prevention in immunocompromised individuals, with a ceiling value of $2,273,213.36.
The order is issued under the PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) parent IDIQ. Place of performance is Urbana, IL. The order is firm fixed price with an ultimate completion date of July 30, 2026.
Government invoicing in the most recent fiscal year (FY2024) reflects 1.8 FTEs and 3,651 contractor hours, with a derived hourly rate of $9.10 per hour. The University of Illinois self-performed all reported labor with no subcontractors. Year-over-year invoicing declined from $32 thousand in FY2023 to $33 thousand in FY2024, though the hourly rate trend is declining.
Quick answers
Who was awarded contract 75N91018F00003?
75N91018F00003 was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on September 17, 2018.
How much is contract 75N91018F00003 worth?
The government has obligated $2,273,213 on 75N91018F00003.
Is contract 75N91018F00003 an order under another contract?
Yes. 75N91018F00003 is a delivery order under HHSN261201500026I, an indefinite delivery contract, on PREVENT Toxicology and Pharmacology Testing (PREVENT TOX).
Was contract 75N91018F00003 competed?
The extent of competition for 75N91018F00003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award